Assessment of Narrowband Ultraviolet B Phototherapy Practices among Indian Dermatologists for Vitiligo Authors: Senkadhir Vendhan, Venkataram Mysore Published: 2026 ABSTRACT Background:Narrowband ultraviolet B (NBUVB) phototherapy is an established treatment for vitiligo. However, real-world practices vary significantly, particularly in dosing strategies, maintenance schedules, and the use of minimal erythema dose (MED) testing, impacting treatment outcomes.Aim and Objectives:To assess NBUVB phototherapy practices among Indian dermatologists, evaluate patient characteristics and treatment outcomes, and identify variations in clinical protocols.Patients and Methods:An online, questionnaire-based survey was conducted among 80 Indian dermatologists who responded actively using NBUVB. The questionnaire was validated through expert review, pilot testing, and reliability assessment before deployment. Validation included content validation by three senior dermatologists with more than 15 years of phototherapy experience to ensure item relevance and clarity. A pilot test among 10 dermatologists confirmed internal consistency. Data were analyzed using descriptive statistics.Results:Among 80 respondents (response rate of 5%), 65% had >10 years’ experience. Most respondents (52.5%) used only NBUVB whole-body units, while others employed combination or targeted phototherapy devices. MED testing was performed by only 30%, typically using visual test dose methods; 70% used empirical starting doses. A 200 mJ/cm² starting dose was most common (60%). Maintenance therapy was administered every 1–2 weeks in 75%. Early clinical improvement was observed after 10–20 sessions, and >50% re-pigmentation in vitiligo occurred after 50–70 sessions in 85%. Acral vitiligo showed a mixed response, with poor or limited response in 60% of cases. Mild erythema (80%) and burning (60%) were the most reported side effects.Limitations:The study is limited by self-reported data, possible recall bias, and lack of detail on MED testing procedures.Conclusion:There is marked variability in NBUVB protocols among Indian dermatologists. Emphasizing standardized guidelines and MED-based personalized dosing could improve therapeutic outcomes and patient safety in vitiligo management. Introduction Vitiligo is a chronic dermatological condition that significantly impacts patients’ quality of life, both physically and psychologically.[1] Narrowband ultraviolet B (NBUVB) phototherapy has emerged as one of the most effective treatment modalities for vitiligo.[23] Despite its widespread use, there is considerable variability in how NBUVB phototherapy is administered across different dermatological centers.[4] Factors such as starting doses, frequency of treatment sessions, and maximum doses vary significantly among practitioners. Moreover, the management of a chronic condition like vitiligo requires ongoing treatment and maintenance, where even small differences in protocol such as estimation of minimal erythema dose (MED) versus empirical initial dosing can significantly impact long-term outcomes.[567] This study focuses on understanding these variations in practice among Indian dermatologists and their impact on treatment outcomes. This study aimed to evaluate current clinical practice patterns among Indian dermatologists using NBUVB phototherapy for vitiligo, analyze patient demographics and treatment characteristics, assess therapeutic outcomes in terms of early and marked clinical improvement, and identify factors contributing to inter-practitioner variability in phototherapy protocols. Patients and Methods Study design This study was conducted as an online survey aimed at assessing the variability in NBUVB phototherapy practices among dermatologists in India and examining how these practices impact treatment outcomes in patients with vitiligo. Participants The questionnaire was distributed to 1,600 dermatologists, of whom 80 responded, yielding a response rate of approximately 5%. The questionnaire was circulated across several WhatsApp groups of dermatologists three times in 6 weeks. All the 80 respondents confirmed active use of phototherapy devices in their practice, meeting the inclusion criteria for the study. This approach ensured that the study focused exclusively on dermatologists with hands-on experience in NBUVB phototherapy. Questionnaire validation The questionnaire underwent a multi-step validation process before data collection. Face and content validation were conducted by a panel of three senior dermatologists specializing in phototherapy, who reviewed each item for clinical relevance, clarity, and comprehensiveness. Following expert feedback, modifications were made to improve the wording and remove redundant items. Subsequently, a pilot study involving 10 dermatologists was carried out to assess reliability and feasibility. Responses from the pilot were statistically analyzed, yielding Cronbach’s alpha coefficient of 0.84, confirming high internal consistency. The final validated instrument was then circulated for data collection. Questionnaire design A structured questionnaire was developed to capture detailed information on several key areas: Demographics and experience: Years of experience in dermatology.Types of phototherapies offered [e.g., NBUVB, psoralen plus ultraviolet-A radiation (PUVA)].Average number of patients treated with NBUVB per month. Years of experience in dermatology. Years of experience in dermatology. Types of phototherapies offered [e.g., NBUVB, psoralen plus ultraviolet-A radiation (PUVA)]. Types of phototherapies offered [e.g., NBUVB, psoralen plus ultraviolet-A radiation (PUVA)]. Average number of patients treated with NBUVB per month. Average number of patients treated with NBUVB per month. Patient characteristics: Age, gender, and Fitzpatrick skin type of vitiligo patients receiving NBUVB. Age, gender, and Fitzpatrick skin type of vitiligo patients receiving NBUVB. Age, gender, and Fitzpatrick skin type of vitiligo patients receiving NBUVB. Treatment protocols: Details on NBUVB treatment protocols, including starting doses, frequency of sessions, and dose adjustments.Use of adjunctive treatments or combination therapies. Details on NBUVB treatment protocols, including starting doses, frequency of sessions, and dose adjustments. Details on NBUVB treatment protocols, including starting doses, frequency of sessions, and dose adjustments. Use of adjunctive treatments or combination therapies. Use of adjunctive treatments or combination therapies. Treatment outcomes: Average number of sessions required to observe early improvement and marked response.Timeframes for significant clinical improvement in vitiligo patients. Average number of sessions required to observe early improvement and marked response. Average number of sessions required to observe early improvement and marked response. Timeframes for significant clinical improvement in vitiligo patients. Timeframes for significant clinical improvement in vitiligo patients. Challenges and variability: Potential challenges in phototherapy, such as patient compliance and management of specific conditions like acral vitiligo.Observed variability in treatment practices and outcomes among patients. Potential challenges in phototherapy, such as patient compliance and management of specific conditions like acral vitiligo. Potential challenges in phototherapy, such as patient compliance and management of specific conditions like acral vitiligo. Observed variability in treatment practices and outcomes among patients. Observed variability in treatment practices and outcomes among patients. Data collection The questionnaire was distributed electronically to 1,600 dermatologists across India through WhatsApp groups and emails. The survey was self-administered, allowing participants to complete it at their convenience. To ensure a high response rate, follow-up reminders were sent via WhatsApp and email. The data collection period spanned three months, providing sufficient time for participants to submit comprehensive responses. Data analysis Data was analyzed using descriptive statistics to summarize demographics, treatment protocols, and outcomes. Categorical variables were presented as frequencies and percentages, while means and standard deviations summarized continuous variables. Comparative analyses explored differences in practice patterns and outcomes based on clinician experience, patient demographics (age, gender, skin type), and treatment protocols (doses, frequency, adjustments). Statistical significance was determined using Chi-square tests for categorical variables and t-tests for continuous variables (P < 0.05). Ethical considerations Participation in the study was voluntary, and informed consent was obtained from all participants. The survey was designed to ensure the confidentiality of respondents, with no personal identifying information collected. The study protocol was reviewed and approved by an Institutional ethics committee (Southern Railway Headquarters Hospital ethics committee, Approval number - D2/10/24 dated 20/10/2024). Results Experience and availability of phototherapy A questionnaire was sent to 1,600 dermatologists across India [Figure 1], including 165 professors, with 80 responding. Their clinical experience ranged from 2–28 years, with 65% having more than 10 years of experience. All confirmed phototherapy device availability in their hospitals/clinics. Visual Representation of respondent’s location Number of phototherapy patients treated monthly Patient caseloads varied, with 40% treating more than 20 patients per month and 60% managing 10–15 patients per month. Types of equipment used for narrowband ultraviolet B phototherapy When categorized into mutually exclusive groups, 52.5% of respondents used only NBUVB whole-body units. An additional 20% reported using NBUVB whole-body units in combination with other phototherapy devices such as UVA, hand–foot units, or excimer lamps. The remaining 27.5% used targeted phototherapy devices alone, including hand–foot units or excimer lamps. Age range of patients and common Fitzpatrick skin types treated with narrowband ultraviolet B Most patients (70%) were aged 18–65 years, 20% were under 18 years, and 10% were above 65 years. Fitzpatrick skin types IV (80%) and V (15%) were the most common among patients undergoing NBUVB phototherapy. Minimal erythema dose MED estimation was performed by 30% of respondents. Among them, the most commonly reported method was a test dose using graded exposures to increasing NBUVB doses on small adjacent skin sites, with erythema assessed at 24 hours post-exposure. Most respondents who performed MED testing used test areas on the back or buttock, in line with standard protocols. However, the majority (70%) relied on empirical fixed-dose initiation without performing formal MED testing, citing logistical challenges and time constraints as common reasons. Typical starting dose of narrowband ultraviolet B The most common starting dose for NBUVB was 200 mJ/cm² (60%), followed by 300 mJ/cm² (17.5%), 400 mJ/cm² (10%), 500 mJ/cm² (3.75%), and 220 mJ/cm² (2.5%). Additionally, 2.5% reported using lower starting doses based on individual patient factors, while 3.75% started at 150 mJ/cm² with gradual escalation. Usual highest dose of narrowband ultraviolet B and the number of sessions for maintenance therapy The highest NBUVB dose varied, with 55% using 2000 mJ/cm², 20% using 1500 mJ/cm², 15% using 1000 mJ/cm², and 10% using 1200 mJ/cm². For maintenance therapy, 75% recommended sessions every 1–2 weeks, while 25% advised sessions every 3–4 weeks. Observed complications of narrowband ultraviolet B Common complications included erythema (80%), burning sensation (60%), blistering (20%), and hyperpigmentation (15%), with 95% describing these as mild and manageable. Management of therapy discontinuation Upon therapy discontinuation, 65% restarted at 50% of the last dose, 25% at 75%, and 10% resumed at the same dose after assessment. Average time to early noticeable improvement and time to marked response in vitiligo Early improvement was typically seen after 10–20 sessions in 70% of respondents. A marked response in vitiligo, defined as more than 50% re-pigmentation, was reported after 50–70 sessions in 85% of respondents. Effectiveness of narrowband ultraviolet B in acral vitiligo NBUVB’s effectiveness in acral vitiligo was mixed, with 40% finding it somewhat effective (<50% re-pigmentation), 35% reporting limited efficacy (<25% re-pigmentation), and 25% considering it ineffective, indicating the need for alternative treatments. The summary of the results is mentioned in Table 1. Table 1Summary of phototherapy practices in IndiaCategorySummaryRespondents and experience80 responses (65% with >10 years’ experience)Phototherapy availability100% availability in clinics/hospitalsMonthly caseload40% treat>20 patients/month; 60% treat 10–15 patients/monthEquipment types used52.5% NBUVB whole-body only; 20% NBUVB whole-body + other devices; 27.5% targeted devices onlyPatient demographics70% aged 18–65 years; 20% under 18 years; 10% above 65 years; skin type IV most common (80%)MED testing30% perform MED testing; rest use empirical dosingStarting doseMost start at 200 mJ/cm² (60%)Highest dose55% go up to 2000 mJ/cm²Maintenance therapy75% recommend every 1–2 weeksCommon complicationsErythema (80%) and burning (60%) are common; mostly mildDose restart after discontinuation65% restart at 50% doseVitiligo responseEarly response in 10–20 sessions; marked in 50–70 sessionsEfficacy in acral vitiligo40% report <50% repigmentation; 25% ineffectiveMED=Minimal Erythema Dose; NBUVB=Narrowband Ultraviolet B Summary of phototherapy practices in India MED=Minimal Erythema Dose; NBUVB=Narrowband Ultraviolet B Discussion This study comprehensively analyzes NBUVB phototherapy practices among Indian dermatologists, revealing significant variations in protocols. More than half of the dermatologists (52.5%) used only NBUVB whole-body units, while the remainder relied on either combination phototherapy setups or targeted devices, highlighting infrastructural variability across centers. The MED is recommended for initiating therapy, yet only 30% utilized it, while 70% relied on empirical dosing (150–500 mJ), likely due to logistical constraints. Although standard guidelines such as British Association of Dermatologists (BAD) guidelines[8] and vitiligo working group recommendations[9] for dose adjustment exist, many practitioners do not follow them consistently. Dose modification practices differ depending on the nature of treatment interruption. In cases of prolonged therapy discontinuation, most dermatologists restarted NBUVB at reduced doses, as reflected in our results. In contrast, for short-term missed sessions, clinicians reported minor dose reductions (typically 20–50%) or resumption of the previous dose, reflecting individual clinical judgment rather than standardized protocols. Previous studies have shown that early clinical improvement with NBUVB phototherapy is typically observed after 20–30 sessions, while a marked response in vitiligo often requires 50 or more sessions.[9] Acral vitiligo has consistently demonstrated lower responsiveness to NBUVB compared to non-acral sites, likely due to reduced follicular melanocyte reservoirs.[10] Reported adverse effects, including erythema and hyperpigmentation, are generally mild, dose-dependent, and reversible, particularly in darker skin types.[51112] Epidemiological studies have also shown that the majority of patients undergoing phototherapy belong to the adult age group, with a smaller proportion of pediatric and elderly patients.[13] While the study captured whether MED estimation was practiced, it did not collect comprehensive procedural data from all respondents. In our own institutional protocol, MED testing is conducted by exposing adjacent 1 × 1 cm² areas of uninvolved skin (usually buttock or mid-back) to ascending doses ranging from 200 to 1000 mJ/cm² in 100 mJ/cm² increments. Erythema is evaluated after 24 hours, and the lowest dose eliciting uniform perceptible erythema is considered the MED. Incorporating a standardized approach to MED testing could reduce inter-practitioner variability and enhance dosing precision, particularly in darker skin types (Fitzpatrick IV–V), where visual erythema may be subtle or delayed.[1415] A study by Alghamdi et al.[16] in Saudi Arabia found similar variability in phototherapy protocols, with 98.2% of dermatologists offering phototherapy, 84% preferring NBUVB for generalized vitiligo, and 31% using MED for dose initiation. Fixed starting doses were used by 68%, and NBUVB was favored for color matching (50%), faster response (37%), and durable pigmentation (31%). Nearly half (47%) of the respondents limited sessions due to skin cancer concerns, though no cases were reported. This aligns with our findings, emphasizing the variability in phototherapy practices and the necessity for adhering to the standardized protocols. Limitations The study relied on self-reported data, which may introduce recall bias or reporting inaccuracies. Additionally, the cross-sectional design captured practice patterns at a single point in time, limiting assessment of temporal changes in phototherapy practices. The relatively low response rate may also affect the generalizability of the findings. Furthermore, although the survey evaluated practice patterns related to NBUVB phototherapy, treatment outcomes were based on clinicians’ observations rather than individual patient-level assessments. Conclusion This study highlights significant variability in NBUVB phototherapy practices among Indian dermatologists, including differences in machine availability, dosing, and dose adjustments. Emphasizing personalized, evidence-based approaches such as MED testing and standardized dose adjustments can improve treatment consistency. Adopting uniform guidelines will enhance efficacy, safety, and patient outcomes in NBUVB therapy. Authors’ contributions Manuscript has been read and approved by all authors, all authors meet authorship criteria and the manuscript represents honest work. Data availability statement Data are available from the corresponding author on reasonable request. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence (AI) The preparation of this manuscript was carried out entirely by the authors without the use of artificial intelligence technologies.